10x Genomics (TXG) Scheduled to Post Earnings on Tuesday

10x Genomics (NASDAQ:TXG) is scheduled to post its quarterly earnings results after the market closes on Tuesday, October 29th. Analysts expect 10x Genomics to post earnings of ($0.34) per share for the quarter. 10x Genomics has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.15. The business had revenue of $153.10 million for the quarter, compared to the consensus estimate of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Trading Up 0.1 %

Shares of NASDAQ TXG opened at $15.49 on Monday. The firm’s 50-day simple moving average is $20.51 and its 200 day simple moving average is $21.80. 10x Genomics has a 12-month low of $14.02 and a 12-month high of $57.90.

Insider Activity

In other news, insider Benjamin J. Hindson sold 4,351 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the sale, the insider now directly owns 345,704 shares of the company’s stock, valued at $7,788,711.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CFO Justin J. Mcanear sold 2,961 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the sale, the chief financial officer now directly owns 143,242 shares of the company’s stock, valued at approximately $3,227,242.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,351 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $98,028.03. Following the sale, the insider now directly owns 345,704 shares of the company’s stock, valued at approximately $7,788,711.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,061 shares of company stock valued at $316,794 in the last ninety days. 10.03% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TXG. JPMorgan Chase & Co. downgraded shares of 10x Genomics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $40.00 to $20.00 in a research report on Thursday, July 18th. Morgan Stanley cut their target price on shares of 10x Genomics from $50.00 to $46.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Jefferies Financial Group upgraded shares of 10x Genomics from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Monday, July 22nd. Leerink Partners assumed coverage on shares of 10x Genomics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 target price on the stock. Finally, The Goldman Sachs Group cut their target price on shares of 10x Genomics from $26.00 to $16.00 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.60.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.